Clinicopathological characteristics and clinical morbidity in high-risk head and neck cutaneous squamous cell carcinoma patients in Western Australia.
Australia
cutaneous squamous cell carcinoma
high risk
outcome
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
08
11
2021
received:
26
09
2021
accepted:
18
11
2021
pubmed:
21
11
2021
medline:
22
6
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
There is no registry data on morbidity and mortality of high-risk cutaneous squamous cell carcinoma (cSCC) in Australia. To examine the clinicopathological features, mortality and morbidity in high-risk cSCC patients in Western Australia (WA). A retrospective cohort study was conducted through hospital record review on cSCC patients discussed at multidisciplinary meetings at the two largest WA hospitals between March 2015 and December 2016. Of 141 patients, 129 were evaluable, with median follow up of 43.9 (range 3.0-53.2) months. Patients were predominantly older males (84%) with significant comorbidities (Charlson Comorbidity Index (CCI) ≥5; 76%) and history of previous nonmelanoma skin cancer (57%) with advanced disease (57% stage IV without distant metastasis; American Joint Committee on Cancer, 7th edition). Pathological high-risk features were common including nodal extracapsular extension (47%) and cranial nerve involvement (16%). Clinical morbidity was significant with a median of 2 (range 0-13) excisions and 2 (range 0-21) cSCC-related hospitalisations for any cSCC event following the index case discussion. Recurrences of the primary index lesion occurred in 60% of patients and 20% had ≥2 recurrences. Median overall survival for patients with nonmetastatic disease was 39.8 (range 25.9-53.7) months and 16.1 (range 0.2-32.0) months for metastatic disease. CCI ≥5, advanced nodal stage and ≥2 recurrences were significantly associated with mortality on multivariable analyses (P < 0.05). Nodal extracapsular extension and any recurrences were identified as significant risk factors for disease-specific mortality on multivariable analyses (P < 0.05). High-risk cSCC patients have significant health needs represented by high-baseline comorbidities, multiplicity of cSCC events and the number of healthcare-associated interventions. There is an unmet need for robust cancer data collection.
Sections du résumé
BACKGROUND
There is no registry data on morbidity and mortality of high-risk cutaneous squamous cell carcinoma (cSCC) in Australia.
AIM
To examine the clinicopathological features, mortality and morbidity in high-risk cSCC patients in Western Australia (WA).
METHODS
A retrospective cohort study was conducted through hospital record review on cSCC patients discussed at multidisciplinary meetings at the two largest WA hospitals between March 2015 and December 2016.
RESULTS
Of 141 patients, 129 were evaluable, with median follow up of 43.9 (range 3.0-53.2) months. Patients were predominantly older males (84%) with significant comorbidities (Charlson Comorbidity Index (CCI) ≥5; 76%) and history of previous nonmelanoma skin cancer (57%) with advanced disease (57% stage IV without distant metastasis; American Joint Committee on Cancer, 7th edition). Pathological high-risk features were common including nodal extracapsular extension (47%) and cranial nerve involvement (16%). Clinical morbidity was significant with a median of 2 (range 0-13) excisions and 2 (range 0-21) cSCC-related hospitalisations for any cSCC event following the index case discussion. Recurrences of the primary index lesion occurred in 60% of patients and 20% had ≥2 recurrences. Median overall survival for patients with nonmetastatic disease was 39.8 (range 25.9-53.7) months and 16.1 (range 0.2-32.0) months for metastatic disease. CCI ≥5, advanced nodal stage and ≥2 recurrences were significantly associated with mortality on multivariable analyses (P < 0.05). Nodal extracapsular extension and any recurrences were identified as significant risk factors for disease-specific mortality on multivariable analyses (P < 0.05).
CONCLUSION
High-risk cSCC patients have significant health needs represented by high-baseline comorbidities, multiplicity of cSCC events and the number of healthcare-associated interventions. There is an unmet need for robust cancer data collection.
Identifiants
pubmed: 34800329
doi: 10.1111/imj.15630
pmc: PMC9324086
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
944-951Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Am J Clin Dermatol. 2011 Jun 1;12(3):147-54
pubmed: 21469759
Drugs. 2018 Nov;78(17):1841-1846
pubmed: 30456447
Australas J Dermatol. 2015 Nov;56(4):258-67
pubmed: 25716064
J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:6-10
pubmed: 31833607
Value Health. 2021 Mar;24(3):377-387
pubmed: 33641772
Actas Dermosifiliogr. 2013 Jun;104(5):367-79
pubmed: 23683506
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32554615
J Clin Oncol. 2014 Feb 1;32(4):327-34
pubmed: 24366933
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Invest Dermatol. 2017 Nov;137(11):2309-2315
pubmed: 28736229
Lancet Oncol. 2020 Feb;21(2):294-305
pubmed: 31952975
J Surg Oncol. 2012 Dec;106(7):811-5
pubmed: 22592943
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
J Am Acad Dermatol. 2013 Jun;68(6):957-66
pubmed: 23375456
Future Oncol. 2021 Feb;17(5):611-627
pubmed: 33052055
Eur J Cancer. 2018 Jun;96:34-43
pubmed: 29665511
Future Oncol. 2019 Sep;15(27):3171-3184
pubmed: 31382778
Lancet Oncol. 2008 Aug;9(8):713-20
pubmed: 18617440
J Clin Oncol. 2020 Sep 1;38(25):2916-2925
pubmed: 32673170
Br J Dermatol. 2020 Jul;183(1):172-174
pubmed: 31972051
Head Neck. 2017 May;39(5):881-885
pubmed: 28252823
JAMA Dermatol. 2013 May;149(5):541-7
pubmed: 23677079
Cancer Med. 2020 Oct;9(20):7381-7387
pubmed: 32578965
Int J Cancer. 1998 Nov 23;78(5):587-93
pubmed: 9808527
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34413166
Int J Dermatol. 2005 Feb;44(2):95-100
pubmed: 15689204
Adv Exp Med Biol. 2014;810:120-40
pubmed: 25207363
Med J Aust. 2017 Oct 16;207(8):339-343
pubmed: 29020905
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2020 Sep 10;38(26):3051-3061
pubmed: 32730186
J Clin Epidemiol. 2004 Dec;57(12):1288-94
pubmed: 15617955
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979